Clinical Trial Update: the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether Leucogen can prevent ribociclib-associated neutropenia in early breast cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)
• Leucogen

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Leucogen, Ribociclib | Phase 2 | Status: NOT_YET_RECRUITING